XTL Biopharmaceuticals Ltd.
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of late-stage pharmaceutical product candidates. The company's primary strategy is to identify and advance proprietary drugs for the treatment of unmet medical needs, with a particular focus on autoimmune diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-24 19:59 |
Foreign Filer Report
Immediate Report
|
English | 134.1 KB | ||
| 2025-10-24 19:59 |
Foreign Filer Report
Immediate Report
|
English | 36.5 KB | ||
| 2025-07-29 08:54 |
Foreign Filer Report
Immediate Report
|
English | 110.3 KB | ||
| 2025-07-29 08:54 |
Foreign Filer Report
Immediate Report
|
English | 36.4 KB | ||
| 2025-07-24 00:45 |
Pre-Annual General Meeting Information
Immediate Report
|
English | 112.7 KB | ||
| 2025-07-24 00:45 |
Foreign Filer Report
Immediate Report
|
English | 36.4 KB | ||
| 2025-06-15 11:36 |
Board/Management Information
Immediate Report of Meeting to be held on July 21, 2025
|
English | 735.8 KB | ||
| 2025-06-15 11:36 |
Foreign Filer Report
Immediate Report of Meeting to be held on July 21, 2025
|
English | 262.4 KB | ||
| 2025-06-15 11:36 |
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on July 21, 2025
|
English | 131.2 KB | ||
| 2025-05-01 01:18 |
Foreign Filer Report
FORM 20-F For the fiscal year ended December 31, 2024
|
English | 5.4 MB | ||
| 2025-05-01 01:18 |
Foreign Filer Report
FORM 20-F For the fiscal year ended December 31, 2024
|
English | 36.3 KB | ||
| 2025-04-07 18:27 |
Board/Management Information
Noam Band was appointed the Chief Executive Officer, Mr. Band replaces Shlomo S…
|
English | 141.8 KB | ||
| 2025-04-07 18:27 |
Foreign Filer Report
Noam Band was appointed the Chief Executive Officer, Mr. Band replaces Shlomo S…
|
English | 36.3 KB | ||
| 2025-03-04 14:39 |
Foreign Filer Report
Definitive Exclusive Sublicense Agreement with Biossil, a company incorporated …
|
English | 116.4 KB | ||
| 2025-03-04 14:39 |
Foreign Filer Report
Definitive Exclusive Sublicense Agreement with Biossil, a company incorporated …
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for XTL Biopharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
